Recurrent adenocarcinoma of the endometrium: A clinical and histopathological study of 379 patients

Aalders, Jan G.; Abeler, Vera M.; Kolstad, Per

doi:10.1016/0090-8258(84)90063-5

Cited by 218 publications

(116 citation statements)

References 23 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…At present, no serum biomarkers are available for screening for endometrial carcinoma or for monitoring recurrence in endometrial carcinoma survivors. Patients with recurrent disease are detected only following the development of symptoms or abnormalities in imaging assessments [11].…”

Section: Introductionmentioning

confidence: 99%

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

Yurkovetsky

Ta’asan

Skates

et al. 2007

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Endometrial carcinoma is the most common gynecologic cancer. Although the prognosis for endometrial cancer is generally good, cancers identified at late stages are associated with high levels of morbidity and mortality. Therefore, prevention and early detection may further reduce the burden of this challenging disease.Methods-A panel of 64 serum biomarkers was analyzed in sera of patients with stages I-III endometrial cancer and age-matched healthy women, utilizing a multiplex xMAP ™ bead-based immunoassay. For multivariate analysis, four different statistical classification methods were used: logistic regression (LR), separating hyperplane (SHP), k nearest neighbors (KNN), and Classification Tree (CART). For each of these classifiers a diagnostic model was created, based on the crossvalidation set consisting of sera from 115 patients with endometrial cancer and 135 healthy women.Results-Our data have demonstrated that patients with endometrial cancer have significantly different expression patterns of several serum biomarkers as compared to healthy controls. Prolactin was the strongest discriminative biomarker for endometrial cancer providing 98.3% sensitivity and 98.0% specificity alone. Our results have revealed that serum concentration of cancer antigens, including CA 125, CA 15-3, and CEA are higher in patients with Stage III endometrial cancer as compared to those with Stage I. In addition, we have shown that the expression of CA 125, AFP and ACTH is elevated in women with tumor grade 3 vs. grade 1. Furthermore, 5-biomarker panel Requests for reprints: Anna Lokshin, University of Pittsburgh Cancer Institute, Hillman Cancer Center, 5117 Centre Ave., Pittsburgh, PA 15213. Phone: 412-623-7706; Fax: 412-623-1415; E-mail: lokshina@pitt.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. (prolactin, GH, Eotaxin, E-selectin, and TSH) identified in this study, was able to discriminate endometrial cancer from ovarian and breast cancers with high sensitivity and specificity. NIH Public AccessConclusions-The ability of prolactin to accurately discriminate between cancer and control groups indicates that this biomarker could potentially be used for development of blood-based test for the early detection of endometrial cancer in high-risk populations. Combining the information on multiple serum markers using flexible statistical methods allows for achieving high cancer selectivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

Yurkovetsky

Ta’asan

Skates

et al. 2007

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…9 Abdul-Karim et al 10 reported the highest incidence, 25%, in a study of bone metastases from the sixty-seven autopsy cases with EC. Only six (8.7%) of these patients had known bone metastases while they were alive and all had high-grade carcinomas.…”

Section: Discussionmentioning

confidence: 99%

“…1 Hematogenous metastasis is less frequent in EC with lung being the most common site of metastatic involvement. 9 Liver, bone, and brain metastases are less common.…”

Section: Discussionmentioning

confidence: 99%

Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature

Kurt¹

2011

UHOD

View full text Add to dashboard Cite

Isolated skeletal metastasis of endometrial carcinoma is very unusual. Herein, we report a 62-year-old woman diagnosed as FIGO stage IC, grade I, endometrial carcinoma who was found to have isolated femur and tibia metastases just after completing local radiotherapy. Incisional biopsy revealed metastatic adenocarcinoma. Following radiotherapy, medroxyprogesterone acetate and zoledronic acid was given. After a month, spontaneous right proximal femur fracture occurred and new bone metastasis was detected. Local radiotherapy and six cycles of paclitaxel and carboplatin were given; however, during a 3-year follow-up, bone metastases progressed. We review the endometrial carcinoma with bone metastasis in literature. Keywords: Endometrial carcinoma, Bone metastasis, Treatment ÖZET Erken Evre Endometrium Adenokanserinde ‹zole Kemik Metastazlar›: Olgu Sunumu ve Literatürün Gözden GeçirilmesiEndometrium kanserinin izole kemik metastaz› çok nadirdir. Burada FIGO evre IC, grad I endometrium kanseri tan›s› konulan, lokal radyoterapisi tamamland›ktan hemen sonra izole femur ve tibia metastazlar› saptanan 62 yafl›nda bayan hasta rapor edilmektedir. ‹nsizyonel biyopsi metastatik adenokarsinomu gösterdi. Radyoterapi sonras›nda medroksiprogesteron asetat ve zoledronik asit verildi. Bir ay sonra, spontan sa¤ proksimal femur k›r›¤› meydana geldi ve yeni kemik metastaz› saptand›. Lokal radyoterapi ile 6 kür paklitaksel ve karboplatin kemoterapisi verildi, ancak kemik metastazlar› progresyon gösterdi. Bu makalede endometrium kanserli hastalarda geliflen kemik metastazlar› literatür eflli¤inde tart›fl›lm›flt›r.

show abstract

“…Brachytherapy is essential for management of primary vaginal cancer where radical surgery is often precluded by significant morbidity [1,2]. Patients with vaginal recurrence of pelvic tumors such as endometrial cancer are infrequently candidates for repeat surgical excision [3], however combination BT and EBRT provides excellent long-term control and is a potentially curative option in localized disease [4,5,6]. Interstitial BT allows for treatment of deeper tumors that would be insufficiently covered by vaginal cylinder intracavitary BT, which is best suited for superficial (≤ 0.5 cm thick) lesions and for adjuvant treatment following hysterectomy [7,8,9].…”

Section: Purposementioning

confidence: 99%

Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies

Onderdonk

Daugherty

Aridgides

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

Recurrent adenocarcinoma of the endometrium: A clinical and histopathological study of 379 patients

Cited by 218 publications

References 23 publications

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature

Institutional experience using interstitial brachytherapy for the treatment of primary and recurrent pelvic malignancies

Contact Info

Product

Resources

About